

Application of New Alternative Methods in Animal Testing

Patrik Zholt Shosh¹, Yana Chernychko¹, Viktoriia Forkosh¹, Rikhard Oros¹, Renata Birov¹, Anita Szikura¹ & Erzsébet Kohut¹

¹Department of Biology and Chemistry, Ferenc Rakoczi II Transcarpathian Hungarian University, 90202 Berehove, Ukraine

ARTICLE INFORMATION

Article history:

Published: May 2026

Keywords:

Animal testing
 3Rs principle
 New Approach Methodologies
 Bioethics

ABSTRACT

Animal experimentation has long been part of natural science research, but ethical, legal and scientific considerations increasingly require alternative approaches. This article reviews selected New Approach Methodologies (NAMs) in relation to the 3Rs principle of Replacement, Reduction and Refinement. It focuses on Adverse Outcome Pathways, bioprinting, organ-on-a-chip technology and in silico models as methods that can reduce reliance on live animals and improve the human relevance of experimental data. Based on a narrative review of foundational and recent literature, the article shows that these methods are not only ethical substitutes, but also tools that can strengthen mechanistic understanding, predictive capacity and biomedical, pharmaceutical and toxicological research. Their implementation still requires validation, standardization and careful interpretation. The article concludes that NAMs should be viewed as complementary tools that can progressively replace certain forms of animal experimentation in modern research practice.

1. Introduction

Animal experimentation has been employed in various fields of natural science research since ancient times. It has contributed to advances in physiology, pharmacology, toxicology and medicine, yet it has also raised persistent ethical questions about the use of sentient organisms for human benefit. In contemporary research, these questions are no longer treated only as moral concerns; they are also connected to legal regulation, scientific validity and social expectations regarding responsible innovation.

1.1 3Rs principle

The ethical and legal framework for the humane use of animals in research is commonly associated with the 3Rs principle developed by Russell and Burch [1]. The central aim of this concept is to replace animal organisms whenever scientifically possible, reduce the number of animals used when replacement is not yet feasible, and refine procedures so that pain, distress and suffering are minimized. The 3Rs therefore do not represent a single method, but a general strategy for making research more ethical and scientifically disciplined. These guidelines are now applied globally in scientific practice. Although numerous procedures have been developed to ensure the more humane use of living organisms in experiments, alternative methods continue to evolve alongside scientific progress. As a result, the 3Rs principle is becoming increasingly precise, modern and applicable to different areas of research [2, 3].

1.2 New Approach Methodologies

New Approach Methodologies (NAMs) are especially important in this process because they enable biological processes to be modeled without, or with substantially less, reliance on live animal organisms. These technologies offer an ethical alternative and may also provide scientifically more reliable data with direct human relevance. Since many NAMs are based on specific cell biology, biochemical pathways and human physiological mechanisms, they can reduce uncertainty arising from interspecies differences and from the extrapolation of animal data to humans [4].

2. Literature Review

2.1 Scientific limitations of animal experimentation

The scientific value of alternative methods lies in their ability to address one of the major limitations of conventional animal experimentation: the difficulty of translating results from one species to another. Animal models often provide valuable information about whole-organism responses, but they cannot fully reproduce human molecular regulation, tissue architecture, immune reactions or disease processes. This does not mean that every animal study is scientifically invalid; rather, it shows why animal experiments should not be treated as the only reliable route to biological knowledge [2, 4].

2.2 Bioethical role of the 3Rs principle

From a bioethical perspective, Replacement is the most ambitious element of the 3Rs because it directly aims to avoid the use of animals. However, Replacement can be partial or complete. Partial replacement may use lower organisms, cell cultures or isolated tissues, while complete replacement relies on non-animal systems such as computational models, engineered tissues or human-based

microphysiological systems. Reduction and Refinement remain relevant when total replacement is not possible, for example by improving experimental design, using better statistical planning and avoiding unnecessary repetition [1, 2].

2.3 Scientific relevance of alternative methods

Recent discussions of alternatives to animal testing emphasize that modern methods should not be understood as simple imitations of animal models. Instead, they can create different types of evidence. Some approaches provide mechanistic information, others predict toxicity or drug activity, and others reproduce specific tissue-level responses under controlled conditions. Therefore, the usefulness of each method depends on the research question, the biological endpoint and the degree of validation required for regulatory or scientific acceptance [2, 4, 6].

3. Methodology

This study is based on a narrative literature review. The sources were collected mainly through Google Scholar, using search terms such as “3Rs principle”, “animal testing alternatives”, “New Approach Methodologies”, “Adverse Outcome Pathways”, “organ-on-a-chip”, “bioprinting”, and “in silico models”. The selected literature was evaluated according to its relevance to bioethics, animal testing reduction and the scientific applicability of alternative methods. Priority was given to recent peer-reviewed studies, review articles and institutional publications related to the replacement, reduction and refinement of animal experimentation.

The reviewed sources were analyzed descriptively, with particular attention to the ethical role of the 3Rs principle and the scientific potential of New Approach Methodologies. The methods discussed in the article were selected because they represent different levels of biological modeling, ranging from molecular pathways and computational prediction to engineered tissues and microphysiological systems. Because the topic is broad, the article does not attempt to cover every available alternative method, but rather highlights representative technologies that demonstrate the direction of current development.

4. Findings

4.1 Adverse Outcome Pathways

An Adverse Outcome Pathway (AOP) is a conceptual map that links biochemical-level effects to adverse outcomes at the organism or population level. The process begins with a molecular initiating event, which triggers a cascade of subsequent biological reactions and eventually leads to a final effect that is significant from an ecological or health perspective. By relying on scientific data such as cellular assays, molecular measurements and computational simulations, AOPs can help researchers identify causal relationships and predict potential harm from early biological signals [5, 6].

4.2 Bioprinting

Bioprinting is a technology that enables the creation of complex bioengineered structures through the precise, layer-by-layer deposition of living cells and biomaterials. The key feature of this method is spatial control: cells can be placed together with proteins, growth factors and other bioactive components in arrangements that support tissue formation. This makes it possible to develop physiologically relevant tissue models that can be used in drug testing, disease modeling and regenerative medicine [6, 7].

4.3 Organ-on-a-Chip Technology

Organ-on-a-chip (OoC) technology integrates microfabrication and tissue engineering to create microfluidic devices where miniaturized human tissues can be maintained under controlled conditions. These devices can simulate key aspects of organ function, including fluid flow, mechanical stimulation and interactions between different cell types. This platform has become important in drug research and pathophysiological studies because it can model human organ responses more directly than many conventional methods [6, 8].

4.4 In Silico Models

In silico models use computational methods, algorithms and virtual simulations to predict biological or chemical behavior. In drug discovery, these approaches can support the identification, testing and optimization of active compounds before laboratory experiments are performed. By processing large datasets and modeling molecular interactions, in silico tools can significantly reduce time and cost in early-stage research [6, 9].

4.5 Comparative Interpretation

The selected methods show that modern alternatives to animal testing are diverse in both purpose and biological scale. AOPs help structure mechanistic knowledge, bioprinting creates engineered tissue models, organ-on-a-chip systems reproduce selected organ-level functions, and in silico models support prediction through computation. As summarized in Table 1, these methods differ in their main function, biological level, contribution to the 3Rs principle and current limitations. Together, they demonstrate that the reduction of animal use is not based on a single replacement technology, but on the combined use of multiple evidence sources.

Table 1: Selected alternative methods and their contribution to the 3Rs principle.

Method	Main function	Contribution to 3Rs	Main limitation	Source
AOPs	Mechanistic pathway mapping	Supports Replacement and Reduction through early prediction	Requires strong evidence for causal links	[5, 6]
Bioprinting	Creation of 3D tissue models	Supports Replacement in tissue-level testing	Limited whole-organism complexity	[6, 7]

RESEARCH ARTICLE

Organ-on-a-chip	Microphysiological organ modeling	Supports Replacement and Reduction in drug and toxicity testing	Requires standardization and reproducibility	[6, 8]
In silico models	Computational prediction and virtual screening	Supports Reduction before laboratory testing	Depends on data quality and validation	[6, 9]

Source: Compiled by the authors based on [5–9].

5. Conclusion and Recommendations

5.1 Conclusion

New alternative methods in animal testing represent a major ethical and scientific advance. AOPs, bioprinting, organ-on-a-chip systems and in silico models support the principles of Replacement, Reduction and Refinement by reducing reliance on animal organisms while improving the human relevance and predictive value of experimental data. Their development indicates that humane research and high-quality science are not opposing goals; rather, they can strengthen each other.

5.2 Recommendations

The main recommendation is that researchers should apply alternative methods intentionally, according to the biological question being studied. NAMs should be integrated into research planning at an early stage, not treated as optional additions after animal experiments have already been designed. Education in the 3Rs principle, better access to validated methods and closer cooperation between scientists, institutions and regulatory authorities can accelerate this transition.

Although animal experiments cannot yet be replaced in every field, the direction of modern research is clear. The long-term goal should be a gradual shift toward methods that are more humane, more human-relevant and more transparent. In this sense, alternative methods are not only technical tools, but also indicators of a broader ethical transformation in scientific practice.

References

- [1] Russell, W. M. S., & Burch, R. L. (1959). *The Principles of Humane Experimental Technique*. London: Methuen.
- [2] Richter, S. H. (2024). Challenging current scientific practice: how a shift in research methodology could reduce animal use. *Lab Animal*, 53(1), 9-12. <https://doi.org/10.1038/s41684-023-01308-9>
- [3] Cedrola, C. C., Cedrola, C. C., de Paula, A. C. C., da Costa, J. D. C., & Vilela, F. M. P. (2025). Alternatives to animal testing in cosmetic products: A patent applications review and future perspectives. *Toxicology in Vitro*, 106187. <https://doi.org/10.1016/j.tiv.2025.106187>
- [4] Sewell, F., McBlane, J., Sturgeon, K., & Dunmore, H.-M. (2025). *Incorporating new approach methodologies in the development of new medicines*. National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs); Medicines & Healthcare products Regulatory Agency (MHRA). <https://nc3rs.org.uk/sites/default/files/2025-09/Incorporating%20new%20approach%20methodologies%20in%20the%20development%20of%20new%20medicines.pdf>
- [5] Ankley, G. T., Bennett, R. S., Erickson, R. J., Hoff, D. J., Hornung, M. W., Johnson, R. D., Mount, D. R., Nichols, J. W., Russom, C. L., Schmieder, P. K., Serrano, J. A., Tietge, J. E., & Villeneuve, D. L. (2010). Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. *Environmental Toxicology and Chemistry*, 29(3), 730-741. <https://doi.org/10.1002/etc.34>
- [6] National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). (2014). *Our vision 2015-2025*. <https://nc3rs.org.uk/sites/default/files/2021-09/NC3Rs%20Our%20Vision%202015-2025.pdf>
- [7] Ozbolat, I. T. (2015). Scaffold-based or scaffold-free bioprinting: competing or complementing approaches? *Journal of Nanotechnology in Engineering and Medicine*, 6(2), 024701. <https://doi.org/10.1115/1.4030414>
- [8] Leung, C. M., de Haan, P., Ronaldson-Bouchard, K., Kim, G.-A., Ko, J., Rho, H. S., Chen, Z., Habibovic, P., Jeon, N. L., Takayama, S., Shuler, M. L., Vunjak-Novakovic, G., Frey, O., Verpoorte, E., & Toh, Y.-C. (2022). A guide to the organ-on-a-chip. *Nature Reviews Methods Primers*, 2(1), Article 33. <https://doi.org/10.1038/s43586-022-00118-6>
- [9] Chang, Y., Hawkins, B. A., Du, J. J., Groundwater, P. W., Hibbs, D. E., & Lai, F. (2023). A guide to in silico drug design. *Pharmaceutics*, 15(1), 49. <https://doi.org/10.3390/pharmaceutics15010049>